Active, not recruiting
Phase 3 Efficacy and Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy
NCT05696717
- Conditions
- Autonomic Nervous System Diseases, Basal Ganglia Diseases, Brain Diseases, +11 more
- Locations
-
- Movement Disorders Center of Arizona Scottsdale, Arizona, United States
- The Parkinson's and Movement Disorder Institute Fountain Valley, California, United States
- UC San Diego Movement Disorder Center La Jolla, California, United States
- David Geffen School of Medicine at UCLA Los Angeles, California, United States